Establishing guideline harmonization and practice standardization may help promote the safe and consistent delivery of radiopharmaceutical therapies.
Society of Nuclear Medicine and Molecular Imaging (SNMMI) | Strategic Alliance Partners
Latest from Society of Nuclear Medicine and Molecular Imaging (SNMMI)
89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
2
How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?
3
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
4
What is Cevostamab’s Mechanism of Action in Multiple Myeloma?
5
